CompletedNCT03325881

Safety study of SHP465 in ADHD

Researchers compared SHP465 and placebo to find out how the approaches affected ADHD symptoms in children with ADHD.

Medication studyAges 6–12United States

The study in practice

Understand this study

Researchers compared SHP465 and placebo to find out how the approaches affected ADHD symptoms in children with ADHD.

Listed age limits: 6 years to 12 years.

Listed locations: Dothan, United States · Little Rock, United States and 37 more locationsSee all locations and recruitment
Activities: Medication described in the protocol · Placebo comparator
Compensation: Payment and expense reimbursement have not been verified.

Study clarity

Study start dateStarted: December 9, 2017

Recruitment status: Completed
Enrollment listed in the registry: 89
Sponsor: Shire
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States
Age range: From 6 Years to 12 Years
Official registry ID: NCT03325881
Official title: Show the full official title
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed

Dothan · Little Rock · Anaheim

36 more locations

FAQ

What did researchers investigate?

Researchers compared SHP465 and placebo to find out how the approaches affected ADHD symptoms in children with ADHD.

Who is behind this study?

The study sponsor is Shire.

Did this study involve medication?

Yes. The study involved medication, including SHP465 and Placebo.

Who was this study for?

Listed age limits: 6 years to 12 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.